Hallmarks of telomeres in ageing research

Journal of Pathology

Volumn 211, Issue 2, 2007, Pages 114-123

  Shay, Jerry W ^a   Wright, W E ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Ageing; Cancer; Telomerase; Telomeres

Indexed keywords

ADENINE; ANTINEOPLASTIC AGENT; CANCER VACCINE; FUNCTIONAL TELOMERASE RNA OLIGONUCLEOTIDE; GUANINE; ONCOLYTIC VIRUS; REPETITIVE DNA; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE REVERSE TRANSCRIPTASE VACCINE; THYMINE; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; APOPTOSIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BONE MARROW DEPRESSION; CANCER CELL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RISK; CANCER SURGERY; CARCINOGENESIS; CATALYSIS; CELL AGING; CELL DIVISION; CELL PROTECTION; CLINICAL TRIAL; DNA DAMAGE; DNA SEQUENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EARLY DIAGNOSIS; ENZYME ACTIVITY; FAMILIAL CANCER; GENE MUTATION; GENETIC DISORDER; GENETIC RISK; GENETIC SCREENING; GERIATRIC DISORDER; HEART INFARCTION; HUMAN; LEUKEMIA; LIFESPAN; MEDICAL RESEARCH; MULTIINFARCT DEMENTIA; NONHUMAN; NONVIRAL GENE THERAPY; OLIGONUCLEOTIDE THERAPY; ONCOGENE; ONCOLYTIC VIROTHERAPY; PATHOPHYSIOLOGY; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; SENESCENCE; STEM CELL; TELOMERE; TISSUE ENGINEERING; VIRAL GENE THERAPY;

AGING; ANIMALS; CELL AGING; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; DNA, NEOPLASM; HUMANS; NEOPLASMS; PRECANCEROUS CONDITIONS; TELOMERASE; TELOMERE;

EID: 33846703426     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2090     Document Type: Review

References (107)

1. Gompertz B. On the nature and function expressivity of the law of human mortality and on a new mode of determining life contingencies. Phil Trans R Soc Lond 1825;115:513-585.
2. Martin GM, Sprague CA, Epstein CJ. Replicative lifespan of cultivated human cells: effect of donors age, tissue and genotype. Lab Invest 1970;23:86-92.
3. Hayflick L, Moorhead PS. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1961;25:585-621.
4. West MD. The cellular and molecular biology of skin aging. Arch Dermatol 1994;130:87-95.
5. West MD, Shay JW, Wright WE, Linksken MHK. Altered expression of plasminogen activator and plasminogen activator inhibitor during cellular senescence. Exp Gerontol 1996;31:175-193.
6. Shay JW, Wright WE. Historical claims and current interpretations of replicative aging. Nature Biotechnol 2002a;20:682-688.
7. Shay JW, Wright WE, Werbin H. Defining the molecular mechanism of human cell immortalization. Biochim Biophys Acta 1991;1072:1-7.
8. Harley CB, Futcher BA, Greider CW. Telomeres shorten during aging of human fibroblasts. Nature 1990;345:458-460.
9. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990;346:866-868.
10. Lindsey J, McGill NI, Lindsey LA, Green DK, Cooke HJ. In vivo loss of telomeric repeats with age in humans. Mutat Res 1991;256:45-48.
11. Zou Y, Sfeir A, Shay JW, Wright WE. Does a senfinel or groups of short telomeres determine replicative senescence? Mol Biol Cell 2004;15:3709-3718.
12. Harley CB. Telomere loss: mitotic clock or genetic time bomb? Mutat Res 1991;256:271-282.
13. Shay JW. Aging and cancer: are telomeres and telomerase the connection? Mol Med Today 1995;1:378-384.
14. Wright WE, Shay JW. The two-stage mechanism controlling cellular senescence and immortalization. Exp Gerontol 1993;27:383-389.
15. Kim N-W, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-2015.
16. Kirkwood TBL. Human senescence. Bioessays 1996;19:1009-1016.
17. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9(4):138-141.
18. Wright WE, Shay JW. Time, telomeres and tumors; is cellular senescence more than an anticancer mechanism. Trends Cell Biol 1995;5:293-296.
19. Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004;23:2919-2933.
20. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizen, bad neighbors. Cell 2005;120:513-522.
21. de Lange T. Mammalian telomeres. In Telomeres, 2nd edn, de Lange T, Lundblad V, Blackburn E (eds). Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 2006; 387-431.
22. von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci 2002;27:339-344.
23. Wu X, Amos CI, Zhu Y, Zhao H, Grossman BH, Shay JW, et al. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst 2003;95:1211-1218.
24. Slagboom PE, Droog S, Boomsma DI. Genetic determination of telomere size in humans: a twin study of three age groups. Am J Hum Genet 1994;55:876-882.
25. Brouilette S, Singh RK, Thompson JR, Goodall AH, Samani NJ. White cell telomere length and risk of premature myocardial infarction. Arterioscler Throm Vasc Biol 2003;23:842-846.
26. von Zglinicki T, Serra V, Lorenz M, Saretzski G, Lenzen-Grossimlighaus R, Gessner R, et al. Short telomeres in patients with vascular dementia: an indicator of low antioxidative capacity and a possible risk factors? Lab lnvest 2000;80:1739-1747.
27. Benetos A, Gardner JP, Zureik M, Labat C, Xiaobin L, Adamopoutos C, et al. Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects. Hypertension 2004;43:182-185.
28. Okuda K, Khan MY, Skurnick J, Kimura M, Aviv H, Aviv A. Telomere attrition of the human abdominal aorta: relationships with age and atherosclerosis. Atherosclerosis 2000;152:391-398.
29. Samani NJ, Boultby R, Butler R, Thompson JR, Goodall AH. Telomere shortening in atherosclerosis. Lancet 2001;358:472-473.
30. Panossian LA, Porter VR, Valenzuela HF, Zhu X, Reback E, Masterman D, et al. Telomere shortening in T cells correlate with Alzheimer's disease status. Neurobiol Aging 2003;24:77-84.
31. Meeker AK, Hicks JL, Iacobuzio-Donahue CA, Montgomery EA, Westra WH, Chan TY, et al. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res 2004;10:317-326.
32. Rudolph KL, Millard M, Bosenberg MW, DePinho RA. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 2001;28:155-159.
33. O'Sullivan JN, Bronner MP, Brentnall TA, Finley JC, Shen WT, Emerson S, et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet 2002;32:280-284.
34. Wiemann SU, Satyanarayana A, Tsahuridu M, Tillmann HL, Zender L, Klempnauer J, et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J 2002;16:935-942.
35. Farazi PA, Glickman J, Jiang S, Yu A, Rudolph KL, DePinho RA. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res 2003;63:5021-5027.
36. Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 2003;361:393-395.
37. Aviv A. Telomeres and human aging: facts and fibs. Sci Aging Knowl Environ 2004;51:43-45.
38. Aviv A, Valdes A, Gardner JP, Swaminathan R, Kimura M, Spector TD. Menopause modifies the association of leukocyte telomere length with insulin resistance and inflammation. J Clin Endocrinol Metab 2006;91:635-640.
39. Andrew T, Aviv A, Falchi M, Surdulescu GL, Gardner JP, Lu X, et al. Mapping genetic loci that determine leukocyte telomere length in a large sample of unselected, female sibling pairs. Am J Hum Genet 2006;78:480-486.
40. Benetos A, Okuda K, Lajemi M, Kimura M, Thomas F, Skurnick J, et al. Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension 2001;37:381-385.
41. Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF, et al. Obesity, cigarette smoking, and telomere length in women. Lancet 2005;366:662-664.
42. Gardner JP, Li S, Srinivasan SR, Chen W Kimura M, Lu X, et al. Rise in insulin resistance is associated with escalated telomere attrition. Circulation 2005;111:2171-2177.
43. Nawrot TS, Staessen JA, Gardner JP, Aviv A. Telomere length and possible link to X chromosome. Lancet 2004;363:507-510.
44. Martin-Ruiz CM, Gussekloo J, van Heemst D, von Zglinicki T, Westendrop RG. Telomere length in white blood cells is not associated with morbidity or mortality in the oldest old: a population-based study. Aging Cell 2005;4:287-290.
45. Bischoff C, Petersen HC, Graakjaer J, Andersen-Ranberg K, Vaupel JW, Bohr VA, et al. No association between telomere length and survival among the elderly and oldest old. Epidemiology 2006;17:190-194.
46. Jeanclos E, Schork NJ, Kyvik KO, Kimura M, Skurnick JH, Aviv A. Telomere length inversely correlates with pulse pressure and is highly familial. Hypertension 2000;36:195-200.
47. Unryn BM, Cook LS, Riabowol KT. Paternal age is positively linked to telomere length of children. Aging Cell 2005;4:97-101.
48. Epel ES, Blackburn EH, Lin J, Dhabhar FS, Adler NE, Morrow JD, et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci USA 2004;101:17312-17315.
49. Martin-Ruis C, Dickinson HO, Key B, Rowan E, Kenny RA, von Zgliniki T. Telomere length predicts poststroke mortality, dementia, and cognitive decline. Ann Neurol 2006;60:174-180.
50. Honig LS, Schupf N, Lee JH, Tang MX, Mayeux R. Shorter telomeres are associated with mortality in those with APOE E4 and dementia. Ann Neurol 2006;60:181-187.
51. Rando T. Prognostic value of telomere length: the long and short of it. Ann Neurol 2006;60:155-157.
52. de Lange T, Shiue L, Meyers RM, Cox DR, Naylor SL, Killery AM, et al. Structure and variability of human chromosome ends. Mol Cell Biol 1990;10:518-527.
53. Blackburn EH. Telomerases. Annu Rev Biochem 1992;61:113-129.
54. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985;43:405-413.
55. Cristofari G, Lingner J. The telomerase ribonucleoprotein particle. In Telomeres, 2nd edn, de Lange T, Lundblad V, Blackburn E (eds). Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 2006; 21-48.
56. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, et al. Telomerase catalytic subunit homologs from fission yeast and humans. Science 1997;277:955-959.
57. Feng J, Funk WD, Wang S-S, Weinrich SL, Avilion AA, Chiu CP, et al. The RNA component of human telomerase. Science 1995;269:1236-1241.
58. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 1996;18:173-179.
59. Bodnar AG, Ouellete M, Frolkis M, Holt SE, Chiu CP, Morin GB, et al. Extension of lifespan by introduction of telomerase in normal human cells. Science 1998;279:349-352.
60. Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative lifespan. Curr Biol 1998;8:279-282.
61. Wright WE, Pereira-Smith OM, Shay JW. Reversible cellular senescence: a two-stage model for the immortalization of normal human diploid fibroblasts. Mol Cell Biol 1989;9:3088-3092.
62. Shay JW, Wright WE. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 2004;25:1-8.
63. Mason PJ, Wilson DB, Bessler M. Dyskeratosis congenita - a disease of dysfunctional telomere maintenance. Curr Mol Med 2005;5(2):59-170.
64. Yamaguchi H, Calado RT, Ly H, Kajigaya S, Baedocher GM, Chanock SJ, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anaemia. N Engl J Med 2005;352:1413-1424.
65. Mitchell JR, Wood E, Collins KA. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 1999;402:551-555.
66. Shay JW, Wright WE. Telomeres in dyskeratosis congenita. Nat Genet 1999;36:437-438.
67. Shay JW, Wright WE. Mutant dyskerin ends relationship with telomerase. Science 2004;286:2284-2285.
68. Vulliamy T, Marrone A, Goldman F, Dearlove A, Bessler M, Mason PJ, et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 2001;413:432-435.
69. Heiss NS, Knight SW, Vulliamy TJ, Klauck SM, Wiemann S, Mason PJ, et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet 1998;19:32-38.
70. Fogarty PF, Yamaguchi H, Wiestner A, Baerlocher GM, Sloand E, Zeng WS, et al. Late presentation of dyskeratosis congenital as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet 2003;362:628-630.
71. Shay JW, Van der Haegen BA, Ying Y, Wright WE. The frequency of immortalization of human fibroblast and mammary epithelial cells transfected with SV40 large T-antigen. Exp Cell Res 1999;209:45-52.
72. Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, DePinho RA, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997;91:25-34.
73. Guyton AC, Hall JE. Transport of oxygen and carbon dioxide in the blood and bodily fluids. In Textbook of Medical Physiology, Guyton AC, Hall JE (Eds). Saunders: Philadelphia, PA, 1966; 513-523.
74. Parrinello S, Samper E, Krtolica A, Goldstein J, Melov S, Campisi J. Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol 2003;5(8):741-747.
75. Shay JW, Bacchetti S. A survey of telomerase in human cancer. Eur J Can 1997;33:787-791.
76. Steinert S, White DM, Zou Y, Shay JW, Wright WE. Telomere biology and cellular aging in non-human primate cells. Exp Cell Res 2002;272:146-152.
77. Cui W, Aslam S, Fletcher J, Wylie D, Clinton M, Clark AJ. Stabilization of telomere length and karyotypic stability are directly correlated with the level of hTERT gene expression in primary fibroblasts. J Biol Chem 2002;277(41):38531-38539.
78. Forsyth NR, Elder FE, Shay JW, Wright WE. Lagomorphs (rabbits, pikas and hares) do not use telomere-directed replicative aging in vitro. Mech Ageing Dev 2005;126:685-691.
79. Oikawa S, Kawanishi S. Site-specific DNA damage at GGG sequence by oxidative stress may accelerate telomere shortening. FEBS Lett 1999;453(3):365-368.
80. Hall DB, Holmlin DB, Barton JK. Oxidative DNA damage through long-range electron transfer. Nature 1996;382(6593):731-735.
81. Kruk PA, Rampino NJ, Bohr VA. DNA damage and repair in telomeres: relation to aging. Proc Natl Acad Sci USA 1995;92(1):258-262.
82. Petersen S, Saretzki G, von Zglinicki T. Preferential accumulation of single-stranded regions in telomeres of human fibroblasts. Exp Cell Res 1998;239(1):152-160.
83. Wright WE, Shay JW. Fundamental differences in human and mouse telomere biology. Nat Med 2000;6:849-851.
84. Shay JW, Wright WE. Telomerase and human cancer. In Telomeres, 2nd edn, de Lange T, Lundblad V, Blackburn E (eds). Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 2005; 81-108.
85. Jakupciak JP, Wang W, Barker PE, Srivastava S, Atha DH. Analytical validation of telomerase activity for cancer early detection-TRAP/PCR-CE and hTERT mRNA quantification assay for high-throughput screening of tumor cells. J Mol Diagn 2004;6(3):157-165.
86. Shay JW, Werbin H, Wright WE. Telomerase assays in the diagnosis and prognosis of cancer. In Telomeres and Telomerase, Chadwick DJ, Cardew G (Eds). Ciba Foundation Symposium 211. Wiley: Chichester, 1997; 148-160.
87. Herbert B-S, Shay JW, Wright WE. Analysis of telomeres and telomerase. In Current Protocols in Cell Biology, Morgan K (Ed). Wiley: New York, 2003; 18.6.6.
88. Shay, JW. Telomerase in cancer: diagnostic, prognostic and therapeutic implications. Cancer J Sci Am 1998;4:26-34.
89. White L, Wright WE, Shay JW. Telomerase inhibitors. Trends Biotechnol 2001;19:114-120.
90. Shay JW, Wright WE. Telomerase: a target for cancer therapy. Cancer Cell 2002;2:257-265.
91. Shay JW. Telomerase therapeutics: telomeres recognized as a DNA damage signal. Clin Cancer Res 2003;9:3521-3525.
92. Gellert GC, Jackson SR, Dikmen G, Wright WE, Shay JW. Telomerase as a therapeutic target in cancer. Drug Discovery Today 2005;2:159-164.
93. Shay JW, Wright WE. Mechanism-based combination telomerase inhibition therapy. Cancer Cell 2005;7:1-2.
94. Shay JW, Wright WE. Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discovery 2006 [first published online].
95. + T lymphocytes. Clin Cancer Res 2004; 10:828-839.
96. Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, et al. Telomerase peptide vaccination: a Phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 2006;55:1553-1564.
97. + cell responses in patients with metastatic prostate cancer. J Immunol 2005;174:3798-3807.
98. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, et al. Extension of lifespan by introduction of telomerase in normal human cells. Science 1998;279:349-352.
99. Shay JW, Wright WE. The use of 'telomerized' cells for tissue engineering. Nat Biotechnol 2000;18:22-23.
100. Robertson DM, Li L, Fisher S, Pearce VP, Shay JW, Wright WE, et al. Characterization of growth and differentiation in a telomerase-immortalized human corneal epithelial cell line. Invest Ophthalmol Vis Sci 2005;46:470-478.
101. Vaughan MB, Ramirez RD, Brown S, Yang JC, Wright WE, Shay JW. A reproducible laser-wounded skin equivalent model to study the effect of aging in vitro. Regen Med 2004;2:99-110.
102. Vaughan MB, Ramirez RD, Wright WE, Minna JD, Shay JW. A three-dimensional model of differentiation of immortalized human bronchial epithelial cells. Differentiation 2006;74:141-148.
103. Poh M, Boyer M, Solan A, Dahl SL, Pedrotty D, Banik SS, et al. Blood vessels engineered from human cells. Lancet 2005;365:2122-2124.
104. Thomas M, Yang L, Hornsby PJ. Formation of normal functional tissue from transplanted adrenocortical cells expressing telomerase reverse transcriptase (TERT). Nat Biotechnol 2000;18:39-42.
105. Morales CP, Holt SE, Ouellette M, Kaur KJ, Yan Y, Wilson KS, et al. Absence of cancer-associated changes in human fibroblasts after immortalization with telomerase. Nat Genet 1999;21:115-118.
106. Steinert S, Shay JW, Wright WE. Transient expression of human telomerase (hTERT) extends the lifespan of normal human fibroblasts. Biochem Biophys Res Commun 2000;273:1095-1098.
107. Hemann MT, Strong MA, Hao LY, Greider CW. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 2001;107:67-77.